3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Breast
1
Conditions
Frailty
12
Neoplasms
11
Ovarian Neoplasms
5
Lymphoma
5
Lung Neoplasms
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Solid Neoplasm
1
Sarcopenia
1
Sarcoma
1
Recurrence
1
Prostate Cancer Cured
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
Geriatric Assessment
×
Clear all
NCT05509751
2026-04-28
SOAR
University of Toronto
Phase NA
Active not recruiting
60 enrolled